NASDAQ:NBRV - Nabriva Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.00 +0.02 (+1.01 %)
(As of 12/9/2018 04:00 PM ET)
Previous Close$2.00
Today's Range$1.93 - $2.03
52-Week Range$1.84 - $6.94
Volume362,804 shs
Average Volume229,612 shs
Market Capitalization$1.34 billion
P/E Ratio-0.80
Dividend YieldN/A
Beta1.8
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Receive NBRV News and Ratings via Email

Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NBRV
Previous Symbol
CUSIPN/A
Phone610-816-6640

Debt

Debt-to-Equity Ratio0.01
Current Ratio7.35
Quick Ratio7.35

Price-To-Earnings

Trailing P/E Ratio-0.80
Forward P/E Ratio-1.04
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.32 million
Price / Sales251.81
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.24 per share
Price / Book0.89

Profitability

EPS (Most Recent Fiscal Year)($2.49)
Net Income$-74,350,000.00
Net Margins-1,064.19%
Return on Equity-87.03%
Return on Assets-75.17%

Miscellaneous

Employees88
Outstanding Shares669,820,000
Market Cap$1.34 billion
OptionableOptionable

Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics PLC - (NASDAQ:NBRV) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.48) by $0.04. The biotechnology company earned $0.85 million during the quarter, compared to the consensus estimate of $1.16 million. Nabriva Therapeutics had a negative net margin of 1,064.19% and a negative return on equity of 87.03%. View Nabriva Therapeutics' Earnings History.

When is Nabriva Therapeutics' next earnings date?

Nabriva Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 15th 2019. View Earnings Estimates for Nabriva Therapeutics.

What price target have analysts set for NBRV?

7 analysts have issued 1 year price targets for Nabriva Therapeutics' shares. Their predictions range from $5.00 to $18.00. On average, they expect Nabriva Therapeutics' share price to reach $11.60 in the next year. This suggests a possible upside of 480.0% from the stock's current price. View Analyst Price Targets for Nabriva Therapeutics.

What is the consensus analysts' recommendation for Nabriva Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nabriva Therapeutics.

What are Wall Street analysts saying about Nabriva Therapeutics stock?

Here are some recent quotes from research analysts about Nabriva Therapeutics stock:
  • 1. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (11/10/2018)
  • 2. Needham & Company LLC analysts commented, "Nabriva announced plans to acquire Zavante, a private company developing IV fosfomycin (Contepo) for the U.S. market. Zavante shareholders will receive 8.2M shares of NBRV stock and up to $97.5M in milestone payments (cash or shares) if certain regulatory/ commercial milestones are met. Although we have modest expectations for new IV antibiotics like Contepo in the hospital Gram- negative space, we believe the transaction is a net positive for Nabriva. No additional commercial infrastructure is needed beyond what is already planned for lefamulin. Zavante announced Phase 3 results 505(b)(2) submission is expected 4Q18. BUY. We recognize Nabriva needs cash, but believe lefamulin is a substantially underappreciated asset that will be relevant outside the challenging hospital setting." (7/25/2018)

Has Nabriva Therapeutics been receiving favorable news coverage?

Media coverage about NBRV stock has been trending somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nabriva Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.

Who are some of Nabriva Therapeutics' key competitors?

Who are Nabriva Therapeutics' key executives?

Nabriva Therapeutics' management team includes the folowing people:
  • Mr. Steven P. Gelone, Pres & COO (Age 50)
  • Dr. Colin Broom, Consultant & Director (Age 62)
  • Mr. Gary L. Sender, Chief Financial Officer (Age 56)
  • Mr. Theodore R. Schroeder, CEO & Director (Age 63)
  • Mr. Thomas Lembck, Chief Information Officer

Who are Nabriva Therapeutics' major shareholders?

Nabriva Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (1.00%), BlackRock Inc. (0.14%), Dimensional Fund Advisors LP (0.09%), Laurion Capital Management LP (0.06%), FMR LLC (0.05%) and Renaissance Technologies LLC (0.04%). Company insiders that own Nabriva Therapeutics stock include Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, George Harrison Talbot, Hbm Healthcare Investments (Ca, Jennifer Schranz, Robert Crotty, Stephen W Webster and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Nabriva Therapeutics.

Which institutional investors are buying Nabriva Therapeutics stock?

NBRV stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Laurion Capital Management LP, FMR LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Clear Harbor Asset Management LLC and JPMorgan Chase & Co.. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster and Vivo Capital Viii, Llc. View Insider Buying and Selling for Nabriva Therapeutics.

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $2.00.

How big of a company is Nabriva Therapeutics?

Nabriva Therapeutics has a market capitalization of $1.34 billion and generates $5.32 million in revenue each year. The biotechnology company earns $-74,350,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Nabriva Therapeutics employs 88 workers across the globe.

What is Nabriva Therapeutics' official website?

The official website for Nabriva Therapeutics is http://www.nabriva.com.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 56 FITZWILLIAM SQUARE, DUBLIN L2, 19406. The biotechnology company can be reached via phone at 610-816-6640 or via email at [email protected]


MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  405
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel